• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HeartSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/16/26 4:15:52 PM ET
    $HSCS
    Industrial Specialties
    Health Care
    Get the next $HSCS alert in real time by email
    hscs20251229_8k.htm
    false 0001468492 0001468492 2026-03-16 2026-03-16 0001468492 hscs:CommonStockCustomMember 2026-03-16 2026-03-16 0001468492 hscs:WarrantsCustomMember 2026-03-16 2026-03-16
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): March 16, 2026
     

     
    HEARTSCIENCES INC.
     
    (Exact name of Registrant as Specified in Its Charter)
     

     
    Texas
    001-41422
    26-1344466
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
             
    550 Reserve Street, Suite 360
     
    Southlake, Texas
     
    76092
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s Telephone Number, Including Area Code: 682 237-7781
     
    n/a
    (Former Name or Former Address, if Changed Since Last Report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock
     
    HSCS
     
    The Nasdaq Stock Market LLC
    Warrants
     
    HSCSW
     
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
     
    Emerging growth company ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     
     

     
     
    Item 2.02 Results of Operations and Financial Condition.
     
    On March 16, 2026, HeartSciences Inc. (the “Company”) issued a press release providing information regarding the Company’s financial and operating results for the quarter ended January 31, 2026, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.
     
    The information contained in Item 2.02 of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
     
    Item 9.01 Financial Statements and Exhibits.
     
    Exhibit
    No.
     
     
    Description
    99.1*
     
    Press Release dated January 31, 2026
    Exhibit 104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
         
    HEARTSCIENCES INC.
           
           
    Date:
    March 16, 2026
    By:
    /s/ Andrew Simpson
         
    Andrew Simpson
    President, Chief Executive Officer and Chairman of the Board of Directors
     
     
    Get the next $HSCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Simpson Andrew was granted 425,000 shares, increasing direct ownership by 571% to 499,382 units (SEC Form 4)

    4 - HeartSciences Inc. (0001468492) (Issuer)

    6/24/26 6:35:36 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Wells David R.

    4 - HeartSciences Inc. (0001468492) (Issuer)

    1/12/26 8:03:32 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Bent Bruce

    4 - HeartSciences Inc. (0001468492) (Issuer)

    1/12/26 8:03:15 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    These Emerging Companies Are Racing Toward Major Catalysts

    DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. NeOnc Technologies Approaches Major Clinical Catalyst NeOnc Technologies (NASDAQ:NTHI) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Pha

    6/23/26 11:11:05 AM ET
    $NTHI
    $BOLD
    $BLZE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets

    Combined company expected to operate under the Fortitude brand and to trade on Nasdaq under the ticker symbol "TUDE"; transaction expected to close in H2 2026 Upon completion of the transaction, Fortitude believes it will be the first publicly traded venture mining platform with a track record of identifying high-conviction, early-stage Proof-of-Work opportunities Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences"), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transacti

    6/23/26 7:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents

    Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced the grant by the European Patent Office (EPO) of European Patent No. EP4252651, titled "Electrocardiogram-Based Assessment of Diastolic Function." The patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data and patient demographic parameters. "Securing European patent protectio

    6/11/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    SEC Filings

    View All

    SEC Form DEFA14A filed by HeartSciences Inc.

    DEFA14A - HeartSciences Inc. (0001468492) (Filer)

    6/25/26 9:17:55 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by HeartSciences Inc.

    DEFA14A - HeartSciences Inc. (0001468492) (Filer)

    6/24/26 5:19:22 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by HeartSciences Inc.

    DEFA14A - HeartSciences Inc. (0001468492) (Filer)

    6/23/26 5:17:09 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Financials

    Live finance-specific insights

    View All

    Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets

    Combined company expected to operate under the Fortitude brand and to trade on Nasdaq under the ticker symbol "TUDE"; transaction expected to close in H2 2026 Upon completion of the transaction, Fortitude believes it will be the first publicly traded venture mining platform with a track record of identifying high-conviction, early-stage Proof-of-Work opportunities Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences"), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transacti

    6/23/26 7:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

    Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 ("FQ1 2026") and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial progress during FQ1 2026 which saw the Company achieve an FDA Breakthrough Device Designation and successfully launched MyoVista Insights. MyoVista Insights™ Software Platform HeartScie

    9/11/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

    Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements during fiscal year 2025, marking a pivotal shift in its strategy to enhance the clinical value of ECGs through AI and cloud-based technologies that can be deployed across diverse healthcare settin

    7/24/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Heart Test Laboratories Inc.

    SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

    12/11/23 8:30:12 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Heart Test Laboratories Inc.

    SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

    11/27/23 4:02:41 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form SC 13D filed by Heart Test Laboratories Inc.

    SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

    6/14/23 5:06:17 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

    Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

    5/7/25 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Adds Key Advisor to its Scientific Advisory Board

    Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has

    2/26/24 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Expands its Scientific Advisory Board

    Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi

    2/12/24 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care